AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2018
Nov 6, 2018
30751_dirs_2018-11-05_4e33ba1f-1210-4f5a-a678-853f097a8cb6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2018-11-01
Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-11-01 | Ordinary Shares | S | 1300 | $159.4538 | Disposed | 278615 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $159.29 to $160.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.